Meeting
2023 ASCO Genitourinary Cancers Symposium
Determining the impact of genomic classifier testing on patient-reported quality of life after prostatectomy: Results from the G-MINOR randomized trial.
Authors
Udit Singhal
University of Michigan (Ann Arbor, MI), Ann Arbor, MI
Udit Singhal , Stephanie Daignault-Newton , Rodney Dunn , Daniel Eidelberg Spratt , Linda Okoth , Felix Y Feng , Anna Johnson , Brian R Lane , Susan Linsell , Ghani Khurshid , Rohit Mehra , Elai Davicioni , Thomas Maatman , Frank Burks , Paul Rodriguez , Eduardo Kleer , Richard Sarle , David Christopher Miller , Michael L. Cher , Todd Matthew Morgan
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer - Advanced,Prostate Cancer - Localized
Sub Track
Symptoms, Toxicities, Patient-Reported Outcomes, and Whole-Person Care
Clinical Trial Registration Number
NCT02783950
Citation
J Clin Oncol 41, 2023 (suppl 6; abstr 345)
DOI
10.1200/JCO.2023.41.6_suppl.345
Abstract #
345
Poster Bd #
M3
Abstract Disclosures
Similar Posters
Poster
2019 Genitourinary Cancers Symposium
Performance of the 17-gene genomic prostate score test in men with prostate cancer (PCa) managed with active surveillance (AS): Results from the Canary Prostate Active Surveillance Study (PASS).
First Author: Daniel W. Lin
Poster
2023 ASCO Genitourinary Cancers Symposium
A randomized phase II trial of neoadjuvant chemokine modulation in patients with localized prostate cancer undergoing radical prostatectomy.
First Author: Karan Jatwani
Poster
2023 ASCO Genitourinary Cancers Symposium
Evaluating p53 nuclear expression and prostate cancer progression in a predominantly African American cohort.
First Author: William Gesztes
Poster
2023 ASCO Genitourinary Cancers Symposium
Planned interim analysis of perioperative safety of fluzoparib combined with abiraterone in the neoadjuvant treatment of locoregional high-risk prostate cancer: Results from multicenter, phase 2 FAST-PC trial.
First Author: Yao Zhu